

REMARKS

In a series of telephone discussions with Examiner John Pak on January 8, 2003, attorney for Applicant learned that Examiner Pak was inclined to transfer this application to another examining group because his examining group does not examine applications wherein a human patient is treated with a medication comprising an enzyme. In the interest of speeding the examination of this application, I pointed out that only some of the claims use an enzyme as a medicament; other claims are directed to administering a non-enzyme agent that promotes the body to produce enzymes. Examiner Pak acknowledged that such claims would fall into his examining group and he could examine such claims.

Examiner Pak would require a preliminary amendment to limit claim 1 to a non-enzyme medicament and deletion of claims directed to enzymes as a medicament. The amendment herein presented fulfills these requirements.

Examiner Pak would also require an election of species in claim 10 to begin the examination of this claim. To that end, claim 10 is amended to place the various medicaments in the order that Applicant believes they should be examined. Applicant hereby elects the species "sulfonylamido derivatives of histamine" as the first species to be examined.

A clean copy of the two amended claims, claim 1 and claim 10 is appended hereto.

=====